Rezolute (RZLT) Stock Price, News & Analysis

Company Overview

Rezolute, Inc. is a clinical-stage biopharmaceutical company focused on developing treatments for rare and metabolic diseases. The company’s research is centered on therapies that address abnormal insulin activity and other conditions involving disrupted glucose regulation.

Rezolute’s leading product candidate is RZ358, an investigational monoclonal antibody designed to reduce the effects of excessive insulin. The therapy is being developed primarily for congenital hyperinsulinism, a rare disorder in which the pancreas produces too much insulin and causes potentially severe, recurrent hypoglycemia. Rezolute has also investigated RZ358 in other forms of hyperinsulinemic hypoglycemia, including conditions associated with insulin-producing tumors.

The company is also developing RZ402, an investigational oral plasma kallikrein inhibitor intended for potential use in diabetic macular edema and other diseases involving vascular leakage. Rezolute conducts its research and development activities through clinical programs and collaborations supporting the advancement of treatments for patients with significant unmet medical needs.

Rezolute is headquartered in Redwood City, California, and was founded by Nevan Elam, who serves as the company’s chief executive officer. Its shares trade on the Nasdaq under the symbol RZLT.

Key Stats

• Today's Range: $3.67 to $3.95
• 50-Day Range: $3.84 to $5.31
• 52-Week Range: $1.07 to $11.46
• Volume: 2.53 million shs
• Average Volume: 1.45 million shs
• Market Capitalization: $369.75 million
• P/E Ratio: N/A
• Dividend Yield: N/A
• Price Target: $9.38
• Consensus Rating: Moderate Buy

Rezolute Stock Analysis - MarketRank™

Rezolute scored higher than 43% of companies evaluated by MarketBeat, and ranked 539th out of 897 stocks in the healthcare sector. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation.

Analyst's Opinion

• Score: 3.9 / 5
• Analyst Rating: Moderate Buy

Consensus Rating

Rezolute has received a consensus rating of Moderate Buy. The company's average rating score is 2.58, and is based on no strong buy ratings, 8 buy ratings, 3 hold ratings, and 1 sell rating.

Upside Potential

Rezolute has a consensus price target of $9.38, representing about 144.1% upside from its current price of $3.84.

Amount of Analyst Coverage

Rezolute has only been the subject of 3 research reports in the past 90 days.

Earnings and Valuation

• Score: 0.6 / 5
• Proj. Earnings Growth: Growing

Earnings Growth

Earnings for Rezolute are expected to grow in the coming year, from ($0.71) to ($0.52) per share.

Price to Earnings Ratio vs. the Market

The P/E ratio of Rezolute is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Earnings Ratio vs. Sector

The P/E ratio of Rezolute is -4.68, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.

Price to Book Value per Share Ratio

Rezolute has a P/B Ratio of 2.06. P/B Ratios below 3 indicates that a company is reasonably valued with respect to its assets and liabilities.

Short Interest

• Score: 0.0 / 5
• Short Interest Level: Bearish

Percentage of Shares Shorted

20.71% of the float of Rezolute has been sold short.

Short Interest Ratio / Days to Cover

Rezolute has a short interest ratio ("days to cover") of 10.98, which indicates bearish sentiment.

Change versus previous month

Short interest in Rezolute has recently increased by 2.87%, indicating that investor sentiment is decreasing.

Dividend

• Score: 0.0 / 5
• Dividend Strength: N/A

Dividend Yield

Rezolute does not currently pay a dividend.

Dividend Growth

Rezolute does not have a long track record of dividend growth.

News and Social Media

• Score: 2.4 / 5
• News Sentiment: N/A

News Sentiment

Rezolute has a news sentiment score of 0.79. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.56 average news sentiment score of Healthcare companies.

News Coverage This Week

MarketBeat has tracked 1 news article for Rezolute this week, compared to 3 articles on an average week.

MarketBeat Follows

Only 3 people have added Rezolute to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days.

Company Ownership

• Score: 1.2 / 5
• Insider Trading: N/A

Insider Buying vs. Insider Selling

In the past three months, Rezolute insiders have not sold or bought any company stock.

Percentage Held by Insiders

14.78% of the stock of Rezolute is held by insiders. A high percentage of insider ownership can be a sign of company health.

Percentage Held by Institutions

82.97% of the stock of Rezolute is held by institutions. High institutional ownership can be a signal of strong market trust in this company.

Company Calendar

• Last Earnings: 5/12/2026
• Today: 9/20/2026
• Next Earnings (Estimated): 9/21/2026
• Fiscal Year End: 6/30/2027

Industry, Sector and Symbol

• Stock Exchange: NASDAQ
• Sector: Healthcare
• Industry: Biotechnology
• Sub-Industry: Biotechnology
• Current Symbol: NASDAQ:RZLT
• CIK: 1509261
• Web: www.rezolutebio.com
• Phone: (650) 206-4507
• Fax: N/A
• Employees: 71
• Year Founded: 2010

Price Target and Rating

• Average Price Target for Rezolute: $9.38
• High Price Target: $20.00
• Low Price Target: $2.00
• Potential Upside/Downside: +144.1%
• Consensus Rating: Moderate Buy
• Rating Score (0-4): 2.58
• Research Coverage: 12 Analysts

Profitability

• EPS (Trailing Twelve Months): ($0.82)
• Trailing P/E Ratio: N/A
• Forward P/E Ratio: N/A
• P/E Growth: N/A
• Net Income: -$74.41 million
• Net Margins: N/A
• Pretax Margin: N/A
• Return on Equity: -58.82%
• Return on Assets: -54.48%

Debt

• Debt-to-Equity Ratio: N/A
• Current Ratio: 15.84
• Quick Ratio: 15.84

Sales & Book Value

• Annual Sales: N/A
• Price / Sales: N/A
• Cash Flow: N/A
• Price / Cash Flow: N/A
• Book Value: $1.86 per share
• Price / Book: 2.06

Miscellaneous

• Outstanding Shares: 96,290,000
• Free Float: 82,060,000
• Market Cap: $369.75 million
• Optionable: Optionable
• Beta: 0.60